ALX Oncology Holdings Inc (ALXO) News

Form 4 - Statement of changes in beneficial ownership of securities

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge PR...

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong...

Form 8-K - Current report

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials...

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ALX Oncology to Host Virtual R&D Day on March 5, 2025

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities